A dramatic response to an immune checkpoint inhibitor plus chemotherapy in a patient with metastatic metaplastic carcinoma of the breast: A case report DOI Creative Commons
Yumiko Koi,

Wakako Tajiri,

Junji Kawasaki

et al.

Thoracic Cancer, Journal Year: 2024, Volume and Issue: 15(28), P. 2073 - 2076

Published: Sept. 1, 2024

We present a unique case of metastatic metaplastic breast carcinoma responding dramatically to immunochemotherapy. A 46-year-old Japanese woman with primary the breast, which was immunohistochemically confirmed be triple-negative cancer, underwent radical surgery, followed by adjuvant chemotherapy an anthracycline and taxane. Since multiple lung metastases were detected two months post-chemotherapy site shown PD-L1-positive, immune checkpoint inhibitor (ICI) pembrolizumab plus gemcitabine/carboplatin initiated. While treatment discontinued after 15 days due suspected drug-induced pneumonitis, significantly shrank no development new lesions for three months. The patient remained alive as approximately recurrence date. This highlights potential immunochemotherapy in treating carcinomas.

Language: Английский

A dramatic response to an immune checkpoint inhibitor plus chemotherapy in a patient with metastatic metaplastic carcinoma of the breast: A case report DOI Creative Commons
Yumiko Koi,

Wakako Tajiri,

Junji Kawasaki

et al.

Thoracic Cancer, Journal Year: 2024, Volume and Issue: 15(28), P. 2073 - 2076

Published: Sept. 1, 2024

We present a unique case of metastatic metaplastic breast carcinoma responding dramatically to immunochemotherapy. A 46-year-old Japanese woman with primary the breast, which was immunohistochemically confirmed be triple-negative cancer, underwent radical surgery, followed by adjuvant chemotherapy an anthracycline and taxane. Since multiple lung metastases were detected two months post-chemotherapy site shown PD-L1-positive, immune checkpoint inhibitor (ICI) pembrolizumab plus gemcitabine/carboplatin initiated. While treatment discontinued after 15 days due suspected drug-induced pneumonitis, significantly shrank no development new lesions for three months. The patient remained alive as approximately recurrence date. This highlights potential immunochemotherapy in treating carcinomas.

Language: Английский

Citations

2